PO:16:235 | Anifrolumab in systemic lupus erythematosus: real-life experience of a single-center cohort
Background. Anifrolumab (ANI) is a monoclonal antibody directed against type 1 interferon receptor. Its use in the treatment of patients with systemic lupus erythematosus (SLE) is becoming more frequent in clinical practice. The aim of this study is to evaluate the efficacy of ANI in SLE without ac...
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
PAGEPress Publications
2025-11-01
|
| Serie: | Reumatismo |
| Soggetti: | |
| Accesso online: | https://www.reumatismo.org/reuma/article/view/2162 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|